Ro Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Ro and How Does Its Prescribing Model Work?

Ro operates as a direct-to-consumer telehealth company that connects patients to licensed physicians and nurse practitioners through an app and web platform. Prescriptions are filled through Ro Pharmacy, an affiliated compounding and dispensing pharmacy, or through major retail chains depending on the product and state. The model is designed to remove the in-person visit barrier, which cuts access friction but also removes the physical exam that many clinical guidelines still recommend for certain conditions.

The Async-First Design and Its Tradeoffs

Most Ro consults begin with a written intake questionnaire rather than a live video call. Asynchronous prescribing is legal in the majority of US states for the conditions Ro treats, but it carries documented risk. A 2021 JAMA Network Open study found that asynchronous telehealth visits for antibiotics resulted in inappropriately broad prescribing in a majority of cases, pointing to a structural weakness in text-only triage that applies across specialties, not just infectious disease. [1]

For GLP-1 agonists and testosterone, the clinical consequences of skipping a baseline physical include missing contraindications. The American Association of Clinical Endocrinology (AACE) 2023 obesity guideline specifies that a personal and family history of medullary thyroid carcinoma or MEN2 must be captured before prescribing semaglutide or tirzepatide. [2] A written questionnaire can theoretically capture this, but there is no published audit confirming Ro's intake systematically screens for all AACE-listed contraindications.

Affiliated Pharmacy and the Compounding Question

Ro Pharmacy is a 503A compounding pharmacy, not a 503B outsourcing facility. The distinction matters. A 503B facility operates under FDA's Current Good Manufacturing Practice (CGMP) standards and may distribute compounded drugs to patients without a patient-specific prescription. A 503A pharmacy compounds for specific patients but is regulated primarily at the state board level, with limited federal oversight. [3]

During the FDA drug shortage designation for semaglutide (which remained active through early 2025), 503A pharmacies like Ro Pharmacy could legally compound semaglutide under federal law. The FDA officially removed semaglutide from the shortage list in March 2025, giving 503A pharmacies until May 22, 2025, to wind down compounding of the active pharmaceutical ingredient. [4] Tirzepatide's shortage designation was resolved earlier. Platforms that continued to compound these drugs after the grace-period deadlines face enforcement risk, and patients ordering from those platforms face receiving a product with no FDA-approved equivalence data.

GLP-1 Prescribing: How Ro's Approach Compares to Clinical Benchmarks

Semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) are FDA-approved for chronic weight management. The evidence base for both is deep.

The Benchmark Trials Ro's Patients Should Be Measured Against

In STEP-1 (N=1,961), subcutaneous semaglutide 2.4 mg once weekly produced a mean 14.9% body-weight reduction at 68 weeks versus 2.4% on placebo (P<0.001). [5] In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean 22.5% body-weight reduction at 72 weeks. [6] These are the outcomes that a patient on a correctly dosed, brand-name or bioequivalent compounded product should approximate, assuming adherence.

The problem is that Ro does not publish outcomes data against these benchmarks. There is no peer-reviewed paper, no public dashboard, and no disclosed retention-adjusted weight-loss figure from Ro's patient population. Competitors in the GLP-1 space, including Noom Med and WeightWatchers Clinic, also lack independent published outcomes, so this gap is industry-wide, but the absence of data is a meaningful limitation for any platform claiming clinical rigor.

Dosing Transparency

Compounded semaglutide sold through telehealth platforms often uses the same titration schedule as the FDA label: 0.25 mg weekly for weeks 1 through 4, escalating to a maximum of 2.4 mg. Ro has published general dosing information on its website, but the specific formulation, excipients, and sterility testing results of Ro Pharmacy's compounded semaglutide are not publicly disclosed. For patients, this means there is no independent way to verify potency before the shortage-period wind-down.

The FDA's guidance on compounded semaglutide notes that "compounded drugs are not FDA-approved and do not undergo FDA's review for safety, effectiveness, or quality." [4] Patients and clinicians must weigh that language against the practical reality that branded Wegovy faced supply shortages that made compounding a reasonable short-term clinical option for many patients.

A Clinical Decision Framework for Evaluating GLP-1 Telehealth Platforms

When assessing any GLP-1 telehealth platform, including Ro, three questions structure the evaluation:

1. Does the intake screen for all contraindications listed in the FDA-approved label and AACE 2023 guidelines?
2. Is the compounding pharmacy 503A or 503B, and what is its state board inspection history?
3. Does the platform publish retention-adjusted outcomes, or only enrollment figures?

Ro currently answers "partly," "503A," and "no" to those three questions, respectively. That profile is not unique to Ro, but it is the profile of a platform where patients should ask specific questions before enrolling.

Erectile Dysfunction Prescribing at Ro

Ro's Roman brand was built on sildenafil and tadalafil prescribing. Both are FDA-approved, generic, low-cost, and well-studied. The evidence base for PDE5 inhibitors is among the strongest in men's health.

Evidence Alignment

Oral PDE5 inhibitors produce clinically meaningful improvement in International Index of Erectile Function (IIEF) scores in roughly 70% of men with organic ED across multiple meta-analyses. [7] Ro prescribes branded and generic sildenafil and tadalafil, which is straightforward and evidence-aligned for the majority of its ED patients.

The concern is not the drug class. It is the async intake. A complete cardiovascular history is required before prescribing any PDE5 inhibitor because of the risk of severe hypotension with co-administered nitrates. The Princeton Consensus III guidelines state that men with intermediate cardiovascular risk require exercise stress testing before PDE5 inhibitor use. [8] A written questionnaire can ask about nitrate use, but it cannot replicate the clinical judgment applied during a face-to-face history and physical, especially when a patient minimizes symptoms.

Chewable and Novel Formulations

Ro markets chewable sildenafil and tadalafil under the "Roman Swipes" and related product lines. Chewable formulations may have altered pharmacokinetics compared to standard tablets, and FDA has not specifically approved any chewable PDE5 inhibitor formulation. These are compounded products subject to the same 503A limitations described above.

Hair Loss Prescribing: Finasteride and Minoxidil

Ro prescribes oral finasteride and topical or oral minoxidil for androgenetic alopecia. Both drugs have FDA approval for hair loss in men; oral minoxidil for women is off-label but increasingly guideline-supported.

Evidence Base

A 2002 landmark trial showed finasteride 1 mg daily produced a 48% increase in hair count from baseline versus -7% on placebo at 24 months (P<0.001). [9] Minoxidil 5% topical solution has FDA approval for androgenetic alopecia in men and is listed as a first-line option in the American Academy of Dermatology (AAD) clinical guidelines. [10]

Sexual Side Effects and Informed Consent

Post-finasteride syndrome remains a subject of active research and regulatory attention. The FDA label for finasteride 1 mg carries warnings about persistent sexual side effects including decreased libido, erectile dysfunction, and ejaculatory dysfunction. The async prescribing model raises legitimate questions about whether patients receive adequate informed consent before starting finasteride through a questionnaire-based intake.

The FDA's MedWatch database contains finasteride adverse event reports from telehealth-prescribed patients, though attribution to any specific platform is not possible from public records. Patients should receive explicit discussion of sexual side effects before starting finasteride regardless of prescribing channel.

Mental Health Prescribing at Ro

Ro acquired Rory (women's health) and expanded into mental health with services covering anxiety, depression, and ADHD evaluation. Mental health prescribing via async telehealth is among the most regulated and contested areas in direct-to-consumer telemedicine.

Regulatory Field for Controlled Substances

Stimulants prescribed for ADHD are Schedule II controlled substances. The DEA's Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person or live video evaluation before prescribing Schedule II drugs. The COVID-19 telehealth waivers that temporarily suspended this requirement expired, with the DEA finalizing rules in 2023 requiring a live two-way audio-visual encounter for stimulant prescriptions unless the patient has an established relationship with a brick-and-mortar provider. [11]

Ro's mental health prescribing practices must comply with these DEA regulations. There is no public indication of DEA enforcement against Ro specifically, but any platform prescribing stimulants must be using video, not async text, for that particular drug class.

Non-Controlled Mental Health Drugs

For SSRIs and SNRIs, async prescribing is legally permissible in most states. Ro prescribes sertraline and escitalopram, both of which are generic, evidence-supported first-line treatments per the APA practice guidelines. The clinical concern mirrors the ED and GLP-1 verticals: adequacy of intake screening for contraindications, drug interactions, and suicidality risk assessment for patients initiating antidepressants.

Complaint Data and Regulatory Standing

BBB Records

Ro is not currently accredited by the Better Business Bureau. The BBB profile for Ro (as of mid-2025) shows a pattern of complaints related to billing disputes, subscription cancellation difficulties, and delayed shipments. BBB complaint counts are not a clinical metric, but billing and fulfillment complaints correlate with patient experience and care continuity.

The Federal Trade Commission (FTC) has taken enforcement actions against several telehealth subscription models for negative-option billing practices. [12] Ro has not been named in FTC enforcement actions as of this writing, but the complaint pattern is consistent with the subscription billing practices the FTC has targeted elsewhere in the industry.

State Medical Board Actions

State medical board disciplinary actions against individual Ro-affiliated physicians are public record but require state-by-state lookup. No multi-state pattern of board action against Ro-affiliated providers was identified in a review of public disciplinary databases, but patients concerned about a specific prescriber can search their state's medical board website directly.

FDA Observations

FDA has issued warning letters to several telehealth-adjacent compounders, though Ro Pharmacy has not appeared on the FDA's public warning letter database as of mid-2025. [13] The FDA's inspection records for 503A pharmacies are less transparently published than 483 inspection observations for 503B facilities, which limits public accountability for compounders in this category.

How Ro Compares to FDA-Approved Alternatives

Patients considering Ro should understand the distinction between receiving a compounded semaglutide product from Ro Pharmacy versus receiving FDA-approved Wegovy from a retail pharmacy through a Ro prescription.

Wegovy (semaglutide 2.4 mg, Novo Nordisk) carries an FDA-approved label, undergoes pre-market review for safety and efficacy, and has a published post-marketing surveillance dataset. Compounded semaglutide does not. After the shortage-period wind-down deadline of May 22, 2025, any 503A pharmacy continuing to compound semaglutide is operating outside the FDA's enforcement discretion framework. [4]

Patients who received compounded semaglutide from Ro before that deadline were not receiving an FDA-approved product, but they were receiving a product that the agency had explicitly permitted given supply constraints. Patients ordering after the deadline should ask Ro directly which product they will receive, including the NDC number if it is a brand-name product.

Is Ro Legit? A Structured Assessment

"Legit" can mean several things in this context: legally operating, clinically sound, or worth the money relative to alternatives.

Legality

Ro holds active business registrations, and its affiliated pharmacy operates under state pharmacy board licensure. Prescriptions are issued by state-licensed practitioners. On a legal operating basis, Ro is a functioning, licensed telehealth entity.

Clinical Soundness

The drugs Ro prescribes for ED (sildenafil, tadalafil) and hair loss (finasteride, minoxidil) are FDA-approved and evidence-supported for those indications. GLP-1 prescribing, during the shortage period, involved compounded products that were legally permitted but not FDA-approved. Mental health prescribing follows legal frameworks, though async intake for certain conditions is a clinical limitation.

The American Telemedicine Association's 2022 clinical guidelines state that "telemedicine should not be used to circumvent clinically necessary in-person evaluations" and that "a complete medication history and contraindication screen is required regardless of visit modality." [14] That standard is achievable through a well-designed async intake, but there is no independent audit confirming Ro meets it consistently.

Value Relative to Alternatives

Generic sildenafil through Ro costs roughly $4 to $10 per dose depending on the formulation, which is comparable to GoodRx pricing at retail pharmacies. For patients who find the async convenience worth that price, the value proposition is reasonable for ED. For GLP-1 prescribing where the product is no longer compounded semaglutide but FDA-approved Wegovy, Ro's value add is primarily the prescription access, not the drug itself.

The absence of published outcomes data means there is no independent basis for claiming Ro achieves better or worse GLP-1 results than any other prescribing channel. Patients lose, on average, roughly 15% of body weight on correctly dosed semaglutide 2.4 mg per STEP-1 regardless of who writes the prescription, assuming the drug is genuine and the dose is correct.